Literature DB >> 7021420

Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro.

A K Duwe, S I Vas, J W Weatherhead.   

Abstract

Commercial fluid used for peritoneal lavage in peritonitis and in peritoneal dialysis suppressed the activity of peripheral blood leukocytes as measured by chemiluminescence, phagocytosis, and bacterial killing. Suppression was found to be due to the low pH and high osmolality of the fluid. The pH was adjusted to noninhibitory levels in vivo within 30 min, whereas osmolality changes were less rapid and remained at inhibitory levels for fluids of high dextrose concentration (4.25%). Chemiluminescence was the most sensitive assay for inhibitory effects of pH and osmolality, as well as for urea and heparin. The metabolic waste product urea at levels normally found in dialysate and heparin at concentrations routinely added to fluid inhibited only chemiluminescence, whereas creatinine and added insulin were not inhibitory. High fluid volume also resulted in a decrease in efficiency of bacterial killing. These results suggest some changes to be made in the treatment of peritonitis and in peritoneal dialysis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7021420      PMCID: PMC350665          DOI: 10.1128/iai.33.1.130-135.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  Antibody-dependent cytolysis of chicken erythrocytes by an in vitro-established line of mouse peritoneal macrophages.

Authors:  W S Walker; A Demus
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

2.  Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages.

Authors:  R C Allen; L D Loose
Journal:  Biochem Biophys Res Commun       Date:  1976-03-08       Impact factor: 3.575

3.  Cellular composition of peritoneal effluent: response to bacterial peritonitis.

Authors:  R M Hurley; D Muogbo; G W Wilson; M A Ali
Journal:  Can Med Assoc J       Date:  1977-11-05       Impact factor: 8.262

Review 4.  Secondary bacterial peritonitis: the biologic basis of treatment.

Authors:  T Hau; D H Ahrenholz; R L Simmons
Journal:  Curr Probl Surg       Date:  1979-10       Impact factor: 1.909

5.  Ideal target organism for quantitative bactericidal assays.

Authors:  A M Hooke; M P Oeschger; B J Zeligs; J A Bellanti
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

6.  Impaired leukocyte function in patients with poorly controlled diabetes.

Authors:  J D Bagdade; R K Root; R J Bulger
Journal:  Diabetes       Date:  1974-01       Impact factor: 9.461

Review 7.  Renal failure and infection.

Authors:  J Z Montgomerie; G M Kalmanson; L B Guze
Journal:  Medicine (Baltimore)       Date:  1968-01       Impact factor: 1.889

8.  H2O2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors.

Authors:  R K Root; J Metcalf; N Oshino; B Chance
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

9.  Chemiluminescence by polymorphonuclear leukocytes from patients with active bacterial infection.

Authors:  A G Barbour; C D Allred; C O Solberg; H R Hill
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

10.  Studies on the cellular immunology of acute bacteremia. I. Intravascular leucocytic reaction and surface phagocytosis.

Authors:  W B WOOD; M R SMITH; W D PERRY; J W BERRY
Journal:  J Exp Med       Date:  1951-12-01       Impact factor: 14.307

  10 in total
  20 in total

1.  Increased expression of CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected CAPD patients.

Authors:  A Brauner; B Hylander; S H Jacobson; A Moshfegh; J Lundahl
Journal:  Inflammation       Date:  2001-12       Impact factor: 4.092

2.  Surface phagocytosis and host defence in the peritoneal cavity during continuous ambulatory peritoneal dialysis.

Authors:  D L Gordon; J L Rice; V M Avery
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

3.  Withdrawal of continuous ambulatory peritoneal dialysis to treat mild peritonitis.

Authors:  D C Pagniez; E MacNamara; F Fortin; L Delvallez; A Fruchart; P Dequiedt; A Tacquet
Journal:  BMJ       Date:  1988-11-05

4.  Treatment of surgical and non-surgical septic multiorgan failure with bicarbonate hemodialysis and sequential hemofiltration.

Authors:  L Gotloib; A Shostak; A Lev; R Fudin; J Jaichenko
Journal:  Intensive Care Med       Date:  1995-02       Impact factor: 17.440

Review 5.  Peritonitis following endoscopic polypectomy in a peritoneal dialysis patient: the need for antibiotic prophylaxis.

Authors:  D J Bac; M van Blankenstein; S de Marie; M W Fieren
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

6.  Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids.

Authors:  H A Verbrugh; W F Keane; W E Conroy; P K Peterson
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

7.  Effect of dialysate fluids on phagocytosis and killing by normal neutrophils.

Authors:  D M Harvey; K J Sheppard; A G Morgan; J Fletcher
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

8.  Extramedullary peritoneal hematopoiesis combined with tuberculosis in a patient with primary myelofibrosis.

Authors:  Su-Jung Kim; Yenna Lee; Sung-Han Kim; Haeryoung Kim; Kyoung-Un Park; Soo-Mee Bang; Jong-Seok Lee
Journal:  Med Oncol       Date:  2008-10-11       Impact factor: 3.064

9.  Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis.

Authors:  H van Bronswijk; H A Verbrugh; H C Heezius; J van der Meulen; P L Oe; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

Review 10.  Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.